In this meta-analysis, 54 case-control studies (42 for G135C polymorphism, 12 for G172T polymorphism) were performed to provide the most comprehensive assessment of the relationship between RAD51 polymorphisms and cancer risk. This evidence concerns the gene RAD51 and cancer.